Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication

Molecular Cell(2021)10.1016/j.molcel.2021.01.035Source: DataRank Database

Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication is a research paper published in Molecular Cell (2021). On theSindex it has a DataRank of 0. It has been cited 135 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access135 citations

Download PDF

Cite:

Linked data & code

pdb doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (14 grants)Impact (FWCI 7.12)OA: bronzeTopics (34)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Tyler L. Dangerfield ORCID,David W. Taylor ORCID,Kenneth A. Johnson ORCID,Jack P. K. Bravo ORCID

Live enrichment

PubMed:33631104 PMC:PMC7843106 OpenAlex:https://openalex.org/W3124465081

Army Research Office

Grant: W911NF-15-1-0120

Welch Foundation

Grant: F-1604

Welch Foundation

Grant: F-1938

Cancer Prevention and Research Institute of Texas

Grant: RR160088

Cancer Prevention and Research Institute of Texas

Grant: W911NF-19-1-0021

National Institutes of Health

Grant: R01AI110577

National Institute of General Medical Sciences

Grant: R01114223

National Institute of General Medical Sciences

Grant: R35GM138348

NIGMS NIH HHS

Grant: R01 GM114223

NIAID NIH HHS

Grant: R01 AI163336

Gilead Sciences

University of Texas at Austin

Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation

National Institute of Allergy and Infectious Diseases

FWCI

7.12

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

bronzeLicense: http://www.elsevier.com/open-access/userlicense/1.0/

journalhttp://www.cell.com/article/S1097276521000551/pdf

publisherhttp://www.cell.com/article/S1097276521000551/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1097276521000551?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1097276521000551?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.molcel.2021.01.035

Fields of Study

SARS-CoV-2 and COVID-19 ResearchViral gastroenteritis research and epidemiologyRNA and protein synthesis mechanisms

MeSH Terms

SARS-CoV-2Adenosine MonophosphateAlanineAntiviral AgentsHumansRNA-Dependent RNA PolymeraseRNA, ViralViral ProteinsVirus ReplicationCatalytic Domain

Keywords

BiologyRNAChromosomal translocationVirologyViral replicationPolymeraseRNA-dependent RNA polymeraseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)RNA polymeraseCoronavirus disease 2019 (COVID-19)NucleosideNucleoside analogueCell biologyDNAMolecular biologyVirusBiochemistryGeneRemdesivirSars-cov-2Covid-19 Treatment

Sustainable Development Goals

SDG 0: Good health and well-being

Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication

FAIR Checklist

Authors (4)

Funding (14 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)